Endoscopic tissue sampling - Part 1 : Upper gastrointestinal and hepatopancreatobiliary tracts. European Society of Gastrointestinal Endoscopy (ESGE) Guideline by Pouw, Roos E. et al.
Endoscopic tissue sampling – Part 1: Upper gastrointestinal
and hepatopancreatobiliary tracts. European Society of Gastro-
intestinal Endoscopy (ESGE) Guideline
Authors
Roos E. Pouw1, Maximilien Barret2, Katharina Biermann3, Raf Bisschops4 , László Czakó5, Krisztina B. Gecse6, Gert de
Hertogh7, Tomas Hucl8, Marietta Iacucci9, Marnix Jansen10, Matthew Rutter11 , Edoardo Savarino12 , Manon C. W.
Spaander13 , Peter T. Schmidt14, Michael Vieth15, Mário Dinis-Ribeiro16, Jeanin E. van Hooft17
Institutions
 1 Department of Gastroenterology and Hepatology,
Amsterdam Gastroenterology Endocrinology
Metabolism, Cancer Center Amsterdam, Amsterdam
University Medical Centers location VUmc,
Amsterdam, The Netherlands
 2 Department of Gastroenterology and Digestive
Oncology, Cochin Hospital and University of Paris,
Paris, France
 3 Department of Pathology, Erasmus Medical Center,
Rotterdam, The Netherlands
 4 Department of Gastroenterology and Hepatology,
University Hospitals Leuven, Leuven, Belgium
 5 First Department of Medicine, University of Szeged,
Szeged, Hungary
 6 Department of Gastroenterology and Hepatology,
Amsterdam University Medical Centers location AMC,
Amsterdam, The Netherlands
 7 Department of Pathology, University Hospitals Leuven,
Leuven, Belgium
 8 Institute for Clinical and Experimental Medicine,
Prague, Czech Republic
 9 Institute of Translational Medicine, Institute of
Immunology and Immunotherapy and NIHR
Birmingham Biomedical Research Centre, University
Hospitals NHS Foundation Trust and University of
Birmingham, Birmingham, UK
10 Department of Histopathology, University College
London Hospital, London, UK
11 Department of Gastroenterology, University Hospital
of North Tees, Stockton-on-Tees, UK
12 Department of Surgery, Oncology and
Gastroenterology, University of Padua, Padua, Italy
13 Department of Gastroenterology and Hepatology,
Erasmus University Medical Center, Rotterdam,
The Netherlands
14 Department of Medicine (Solna), Karolinska Institute
and Department of Medicine, Ersta Hospital,
Stockholm, Sweden
15 Institute of Pathology, Friedrich-Alexander University
Erlangen-Nuremberg, Klinikum Bayreuth, Bayreuth,
Germany
16 Department of Gastroenterology, Portuguese
Oncology Institute of Porto, Porto, Portugal
17 Department of Gastroenterology and Hepatology,







© 2021. European Society of Gastrointestinal Endoscopy
All rights reserved.
This article is published by Thieme.
Georg Thieme Verlag KG, Rüdigerstraße 14,
70469 Stuttgart, Germany
Corresponding author
Roos E. Pouw, MD PhD, Dept. of Gastroenterology and
Hepatology, Amsterdam University Medical Centers, location





Supplementary material is available under
https://doi.org/10.1055/a-1611-5091






























Adequate collection and handling of tissue samples during
endoscopy is fundamental in diagnosing pathology of the
digestive system. The aim of this guideline was to make
evidence-based recommendations on the indications and pro-
tocols for endoscopic tissue sampling for the most common
conditions in the upper and lower gastrointestinal tracts and
the hepatopancreatobiliary (HPB) tract (the lower gastrointesti-
nal tract will be covered in Part 2 and published separately).
2 Methods
The European Society of Gastrointestinal Endoscopy (ESGE)
commissioned this Guideline (Guideline Committee chair,
J.v.H.) and appointed a guideline leader (R.P.) who invited the
listed authors to participate in the project development. After
the project group had been assembled, task forces were
formed to define the key questions and PICOs (population, in-
tervention, comparator, outcome) in the upper gastrointesti-
nal, lower gastrointestinal, and HPB domains (Table 1 s, see
online-only Supplementary material). Literature searches and
reviews of the relevant articles were performed between March
and September 2020. The available evidence was graded
according to the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) system [1]. Based on
the available evidence, recommendations and suggestions
were drafted and discussed with the project group during on-
line meetings. Further details on the methodology of ESGE
guideline development have been reported elsewhere [2].
In February 2021, a draft prepared by the leaders and coor-
dinating team was sent to all group members. The manuscript
was also reviewed by two independent reviewers and sent for
further comments to the ESGE National Societies and individual
MAIN RECOMMENDATIONS
1 ESGE recommends that, where there is a suspicion of
eosinophilic esophagitis, at least six biopsies should be tak-
en, two to four biopsies from the distal esophagus and two
to four biopsies from the proximal esophagus, targeting
areas with endoscopic mucosal abnormalities. Distal and
proximal biopsies should be placed in separate containers.
Strong recommendation, low quality of evidence.
2 ESGE recommends obtaining six biopsies, including from
the base and edge of the esophageal ulcers, for histologic
analysis in patients with suspected viral esophagitis.
Strong recommendation, low quality of evidence.
3 ESGE recommends at least six biopsies are taken in cases
of suspected advanced esophageal cancer and suspected
advanced gastric cancer.
Strong recommendation, moderate quality of evidence.
4 ESGE recommends taking only one to two targeted biop-
sies for lesions in the esophagus or stomach that are poten-
tially amenable to endoscopic resection (Paris classification
0-I, 0-II) in order to confirm the diagnosis and not compro-
mise subsequent endoscopic resection.
Strong recommendation, low quality of evidence.
5 ESGE recommends obtaining two biopsies from the
antrum and two from the corpus in patients with suspected
Helicobacter pylori infection and for gastritis staging.
Strong recommendation, low quality of evidence.
6 ESGE recommends biopsies from or, if endoscopically
resectable, resection of gastric adenomas.
Strong recommendation, moderate quality of evidence.
7 ESGE recommends fine-needle aspiration (FNA) and fine-
needle biopsy (FNB) needles equally for sampling of solid
pancreatic masses.
Strong recommendation, high quality evidence.
8 ESGE suggests performing peroral cholangioscopy (POC)
and/or endoscopic ultrasound (EUS)-guided tissue acquisi-
tion in indeterminate biliary strictures. For proximal and
intrinsic strictures, POC is preferred. For distal and extrinsic
strictures, EUS-guided sampling is preferred, with POC
where this is not diagnostic.
Weak recommendation, low quality evidence.
9 ESGE suggests obtaining possible non-neoplastic biopsies
before sampling suspected malignant lesions to prevent
intraluminal spread of malignant disease.
Weak recommendation, low quality of evidence.
10 ESGE suggests dividing EUS-FNA material into smears
(two per pass) and liquid-based cytology (LBC), or the
whole of the EUS-FNA material can be processed as LBC,
depending on local experience.
Weak recommendation, low quality evidence.
SOURCE AND SCOPE
This Guideline is an official statement of the European
Society of Gastrointestinal Endoscopy (ESGE). It provides
guidance on the collection and handling of tissue samples
during endoscopy of the upper gastrointestinal and hepa-
topancreatobiliary tracts. The Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE)
system was adopted to define the strength of recommen-
dations and the quality of evidence.





























members. After agreement on a final version, including the
agreed recommendations (a summary of the upper gastro-
intestinal tract recommendations is given in ▶Table 1), the
manuscript was submitted to the journal Endoscopy for publica-
tion. All authors agreed on the final revised manuscript.
This Guideline was issued in 2021 and will be considered for
review and update in 2026, or sooner if new and relevant evi-
dence becomes available. Any updates to the Guideline in the
interim will be noted on the ESGE website: http://www.esge.
com/esge-guidelines.html.
3 Upper gastrointestinal tract
3.1 Eosinophilic esophagitis
Biopsies should be obtained in patients in whom eosino-
philic esophagitis is a clinical possibility, even when normal
mucosa is visualized. Inflammatory alterations in eosinophilic
esophagitis are frequently patchy, therefore it is recommended
that at least six biopsies should be obtained from at least two
different locations in the esophagus, typically two to four biop-
sies from both the distal and proximal esophagus, depending
on where most endoscopic abnormalities are visualized. The di-
agnostic sensitivity increases with the number of biopsies and is
maximized with at least six biopsies. Esophageal biopsies
should be targeted to areas of endoscopic abnormality, mainly
white stipples, exudates, and longitudinal furrows, which are
associated with higher eosinophil counts. In patients with
symptoms, biopsies should also be taken even if the endoscopic
appearance is normal, as this has been reported in up to 10% of
adult patients [3–7].
For patients who are treated with a proton pump inhibitor
(PPI), elimination diet, or steroids, the response to therapy can
be assessed by means of a follow-up endoscopy after a 6- to 12-
week initial course, obtaining at least six biopsies from at least
two different locations in the esophagus, typically two to four
biopsies from both the distal and proximal portions of the
esophagus. However, there is little evidence to support this in
patients who respond to therapy. For patients who respond to
a PPI, elimination diet, or steroids and are maintained on these
treatments, current data do not support follow-up with endo-
scopic and histologic assessment [3–7].
3.2 Gastroesophageal reflux disease
In patients with complaints of gastroesophageal reflux, with
or without PPI use, and with or without endoscopic signs of ero-
sive esophagitis, biopsies are not recommended to confirm
gastroesophageal reflux disease (GERD). For this indication,
RECOMMENDATION
ESGE recommends that, where there is a suspicion of
eosinophilic esophagitis, at least six biopsies should be
taken, two to four biopsies from the distal esophagus
and two to four biopsies from the proximal esophagus,
targeting areas with endoscopic mucosal abnormalities.
Distal and proximal biopsies should be placed in separate
containers.
Strong recommendation, low quality of evidence.
RECOMMENDATIONS
ESGE suggests, in histologically confirmed eosinophilic
esophagitis, obtaining biopsies after a 6- to 12-week
initial treatment course, with at least two to four biopsies
from the distal esophagus and two to four biopsies from
the proximal esophagus, focusing on areas with endo-
scopic mucosal abnormalities.
Weak recommendation, very low quality of evidence.
ESGE suggests against endoscopy and histologic assess-
ment on an annual basis for patients who have responded
to therapy and are maintained on these treatments.
Weak recommendation, very low quality of evidence.
RECOMMENDATION
ESGE recommends against obtaining biopsies for the
diagnosis of gastroesophageal reflux disease (GERD) in
patients with normal endoscopic findings.
Strong recommendation, low quality of evidence.
ABBREVIATIONS
CMV cytomegalovirus
ERCP endoscopic retrograde cholangiopancreato-
graphy
ESGE European Society of Gastrointestinal Endoscopy
EUS endoscopic ultrasound
FGP fundic gland polyp
FNA fine-needle aspiration
FNB fine-needle biopsy
GERD gastroesophageal reflux disease
GRADE Grading of Recommendations Assessment,
Development and Evaluation
HIV human immunodeficiency virus
HPB hepatopancreatobiliary
HSV herpes simplex virus
LBC liquid‑based cytology
MALT mucosa-associated lymphoid tissue
MAPS management of precancerous conditions and
lesions in the stomach
PICO population, intervention, comparator, and
outcome
POC peroral cholangioscopy
PPI proton pump inhibitor
ROSE rapid onsite evaluation




























the sensitivity and specificity of the histologic findings have
insufficient diagnostic accuracy and alternative diagnostic
methods with higher sensitivity and specificity are available
(e. g. reflux monitoring). Biopsies can be considered to exclude
alternative diagnoses, if these are suspected based on the
patient’s symptoms [8–16].
3.3 Infectious esophagitis
▶Table 1 Summarized recommendations for tissue sampling in the upper gastrointestinal tract.
Suspected diagnosis or indication Number and location of biopsies Remarks
Eosinophilic esophagitis: initial
diagnosis or evaluation of therapy
response
At least six biopsies, two to four biopsies from the distal esophagus and
two to four biopsies from the proximal esophagus, targeting areas with
endoscopic mucosal abnormalities
Place biopsies from the distal
and proximal esophagus into
separate containers
Gastroesophageal reflux disease Biopsies not indicated for diagnosis
Infectious esophagitis
▪ Candida esophagitis Given the high positive predictive value of white plaque-like lesions for
candida, biopsies are only indicated if the results would have therapeutic
consequences
Mycologic analysis only in-
dicated for treatment resist-
ance
▪ Viral esophagitis Six biopsies, including from the base and the edge of esophageal ulcers
Barrett’s esophagus In cases with endoscopic evidence of Barrett’s esophagus > 1 cm, biopsies
should be taken from all visible abnormalities; in addition, random four-
quadrant biopsies should be collected every 2 cm within the Barrett’s
segment, starting from the upper end of the gastric folds
Place biopsies from any
abnormalities and from each
level into separate containers
Esophageal cancer and early neo-
plasia
At least six biopsies in cases of suspected advanced cancer
Only one to two targeted biopsies for lesions that are potentially
amenable to endoscopic resection
Dyspepsia and gastritis Two biopsies from the antrum and two from the corpus in patients where
H. pylori is suspected
If staging systems are to be used in patients with atrophy or intestinal
metaplasia (e. g. OLGA, OLGIM), a biopsy in the angle should also be
performed
Place biopsies from antrum
and corpus in separate con-
tainers
Gastric polyps
▪ Fundic gland polyp Standard biopsies are not required
▪ Hyperplastic polyp Biopsy (or resect) if size is > 10mm
▪ Adenoma Biopsy or, if endoscopically resectable, resect
Gastric cancer and early neoplasia At least six biopsies in cases of suspected advanced cancer
Only one to two targeted biopsies for lesions that are potentially
amenable to endoscopic resection
For suspected linitis plastica, at least 10 bite-on-bite biopsies, targeting
mucosal abnormalities
Celiac disease At least six biopsies from different locations in the duodenum, including
two samples from the bulb
Biopsies can be collected in
one container
OLGA, operative link for gastritis assessment; OLGIM, operative link on intestinal metaplasia assessment.
RECOMMENDATIONS
ESGE suggests only obtaining biopsies in cases of
suspected candida esophagitis if results are expected to
have therapeutic consequences. Esophageal biopsies
targeted at white plaque-like lesions should be sent for
histologic and mycologic analysis when there is treat-
ment resistance.
Weak recommendation, very low quality of evidence.
ESGE recommends obtaining six biopsies, including from
the base and edge of the esophageal ulcers, for histologic
analysis in patients with suspected viral esophagitis.
Strong recommendation, low quality of evidence.





























The most frequent cause of infectious esophagitis is fungal
infection by Candida species. When associated with oropharyn-
geal thrush, upfront empiric antifungal treatment can be con-
sidered, as the positive predictive value of oral thrush for candi-
da esophagitis in a patient with dysphagia reaches 77% [17,
18]. If treatment fails or there is an absence of oropharyngeal
lesions, endoscopic inspection and possible sampling of the
esophageal mucosa is needed. An endoscopic diagnosis of can-
dida esophagitis may be made by the observation of white or
yellowish, plaque-like lesions (so called “cottage-cheese”
plaques), and exudates on the esophageal mucosa, which are
usually easily removable. White plaque-like lesions on the
esophageal mucosa have a positive predictive value for candida
esophagitis of 88%–90% [19]. The sensitivity of endoscopic
biopsies with histologic assessment ranges from 54% to 95%
[20–22]. Endoscopic biopsies with fungal culture may be need-
ed in treatment-resistant cases.
In patients with esophageal ulcers, viral esophagitis should
be suspected, most commonly caused by herpes simplex virus
(HSV 1 or 2) and cytomegalovirus (CMV) [23]. In human immu-
nodeficiency virus (HIV)-infected patients, idiopathic esopha-
geal ulcers must also be considered in the differential diagno-
sis, as this has therapeutic consequences because these idio-
pathic esophageal ulcers are best treated with corticosteroids.
Whereas HSV typically presents with ulcers in immunocompro-
mised patients, in elderly patients it may present with vesicles
and “volcano-shaped” mucosal structures. Conflicting data on
the recommended number of endoscopic biopsies is possibly
explained by the need to perform biopsies on the ulcer edge to
observe the cytopathogenic effect of HSV and on the ulcer base
for CMV [24]. Biopsies have a sensitivity of 68%–100% for HSV
and 90%–100% for CMV [24–33].
Viral culture, although highly specific [24], is not available in
most centers [34]. The only prospective study in the field did
not observe an added diagnostic value of viral culture over rou-
tine histologic evaluation with immunohistochemical staining
for CMV and HSV antigens [24]. Furthermore, the use of immu-
nohistochemistry has not been consistently shown to improve
detection of HSV and CMV [35]. Finally, routine hematoxylin
and eosin staining is accurate for the diagnosis of most cases
of viral esophagitis; immunohistochemical staining can be of
help in selected cases.
Besides candida, HSV, and CMV esophagitis, other rare
causes of infectious diagnoses should be kept in mind in the
presence of esophageal ulceration, such as Epstein–Barr virus,
Leishmania, and tuberculous esophagitis.
3.4 Barrett’s esophagus
For evidence, please refer to the existing ESGE position
statement [36]. No new evidence is available on this statement.
3.5 Esophageal cancer and early neoplasia
High definition white-light upper gastrointestinal endoscopy
using standard or virtual chromoendoscopy with biopsy is the
recommended diagnostic modality for all suspected cases of
esophageal cancer. Any lesion suspicious for cancer should be
sampled and sent to pathology in a separate container. In cases
with potentially malignant esophageal stenosis, an ultrathin
endoscope should be used to complete the esophagogastro-
duodenoscopy and obtain tissue samples from inside the
stenosis. The sensitivity of endoscopic forceps biopsies for
esophageal cancer ranges from 92% for a single biopsy to 100%
for six biopsies [37–39]. There is no role for cytology [40].
Early esophageal neoplasia is best staged and treated by
endoscopic resection. Furthermore, extensive biopsy sampling
can jeopardize subsequent endoscopic resection by inducing
submucosal fibrosis. Therefore, where there is a suspected neo-
plastic esophageal lesion that is potentially amenable to endo-
scopic resection (Paris type 0-I or 0-II), one to two endoscopic
biopsies, targeted on the most suspicious parts of the lesion,
should be taken to document the presence of dysplasia or neo-
plasia.
Conversely, where a lesion is not amenable to endoscopic
resection (esophageal stenosis, Paris type ≥0-III), at least six
endoscopic biopsies should be obtained [41]. ▶Fig. 1 illustrates
examples of early and advanced esophageal neoplasia.
RECOMMENDATIONS
ESGE recommends at least six biopsies are taken in cases
of suspected advanced esophageal cancer.
Strong recommendation, moderate quality of evidence.
ESGE recommends taking only one to two targeted biop-
sies for lesions that are potentially amenable to endo-
scopic resection (Paris classification 0-I, 0-II) in order to
confirm the diagnosis and not compromise subsequent
endoscopic resection.
Strong recommendation, low quality of evidence.
RECOMMENDATION
ESGE recommends that, in patients with endoscopic evi-
dence of Barrett’s esophagus of > 1 cm, biopsy samples
should be taken from all visible mucosal abnormalities.
In addition, random four-quadrant biopsies should be
collected every 2 cm within the Barrett’s segment, start-
ing from the upper end of the gastric folds. Biopsies from
each level should be collected in and presented to the
pathologist in a separate container.
Strong recommendation, high quality of evidence.




























3.6 Dyspepsia and gastritis
Helicobacter pylori is a potentially curable cause of dyspepsia,
peptic ulcer disease, and gastric adenocarcinoma or mucosa-
associated lymphoid tissue (MALT) lymphoma. The manage-
ment of H. pylori infection was consecutively summarized in
the Maastricht/Florence Consensus Report [42]. The indica-
tions for endoscopy-based diagnosis vary according to the a
priori chance of malignancy or previous treatments, and are
beyond the scope of this guideline.
During such procedures, biopsies should be performed in
the antrum and corpus. The need to assess both compartments
is drawn from indirect evidence of the patchy distribution in the
corpus in surgical specimens and that, with age and expansion
of pyloric glands, a distal to proximal gastric spread of H. pylori
occurs [43–45]. Moreover, according to the management of
precancerous conditions and lesions in the stomach (MAPS)
guidelines, biopsies should be taken with the purpose of
staging atrophy/intestinal metaplasia as this will affect the allo-
cation to different surveillance strategies [46]. Different con-
tainers should be used for specimens from the antrum and the
corpus. A single container may be enough according to local
expertise, both of the pathologists and the endoscopists, after
proper training and if the endoscopic risk of extensive intestinal
metaplasia is diminutive or during surveillance of individuals
with known atrophic status [47]. If staging systems are to be
used in patients with atrophy or intestinal metaplasia (e. g.
OLGA, OLGIM), a biopsy in the angle should also be performed
as described extensively in the ESGE MAPS-II guideline.
This evidence refers to the existing ESGE guideline [46]. No
new evidence is available on this statement.
3.7 Gastric polyps
Gastric polyps are commonly encountered lesions during
routine endoscopy. They are usually asymptomatic and non-
neoplastic, and may be found sporadically or in association
with polyposis syndromes. Some gastric polyps may have malig-
nant potential. Gastric polyps can be mainly distinguished as
fundic gland polyps (FGPs), hyperplastic polyps, and adenoma-
tous polyps and can mostly be classified endoscopically based
on their typical endoscopic appearance (▶Fig. 2). Biopsies for
classification are therefore superfluous but may be considered
if in doubt and if the outcome has clinical relevance. For an
endoscopically resectable polyp with the need for a histologic
diagnosis, resection is preferred over biopsies, because biop-
sies may underestimate the neoplastic progression risk owing
to sampling error.
▶ Fig. 1 Endoscopic images of esophageal neoplasia showing: a, b early Paris type 0-IIb squamous cell cancer from the 4–10 o’clock position
on: a white-light endoscopy (WLE); b narrow-band imaging (NBI); c, d early Paris type 0-IIa-IIb adenocarcinoma from the 12–4 o’clock position
in a short segment Barrett’s esophagus on: c WLE; d NBI; e, f advanced esophageal squamous cell cancer on: e WLE; f NBI; g, h advanced distal
esophageal adenocarcinoma on: g antegrade view; h retroflexed view.
RECOMMENDATIONS
ESGE recommends obtaining two biopsies from the
antrum and two from the corpus in patients with suspect-
ed Helicobacter pylori infection and for gastritis staging.
Strong recommendation, low quality of evidence.
ESGE recommends placing biopsies from the antrum and
corpus into separate containers.
Strong recommendation, high quality of evidence.





























3.7.1 Fundic gland polyps
FGPs are the most frequently encountered gastric polyps.
They are usually found in patients with chronic PPI use or in
association with polyposis syndromes. A diagnosis of FGPs is
often made based on the endoscopic appearance. FGPs are
usually present in the fundus and gastric body. They are charac-
terized by their small size (< 10mm) and luminous, glossy
appearance (▶Fig. 2a).
Neoplastic features are rarely found in FGPs, with the excep-
tion of FGPs on the background of a polyposis syndrome. Case
series of FGPs reveal low grade dysplasia (LGD) in < 1% of FPGs
[48, 49]. There have been limited case reports published on the
occurrence of high grade dysplasia (HGD) and gastric carcin-
oma in FGPs [50–52]. Large (> 10mm) FGPs seem to have a
slightly higher risk for the presence of dysplasia or focal cancer
compared with small (< 10mm) FGPs [53]. The risk of malignant
progression of sporadic or PPI-associated FGPs is very low. In
cases where FGPs have atypical features, size of > 1 cm, antral
location, ulceration, or unusual appearance, biopsies of the
FGP can be considered.
3.7.2 Hyperplastic polyps
Gastric hyperplastic (hyperplasiogenic) polyps are a result of
chronic inflammation of the gastric mucosa, mainly due to
H. pylori infection or autoimmune gastritis. They appear as soli-
tary, sessile or pedunculated lesions with an eroded surface and
are mainly located in the antrum (▶Fig. 2b). Multiple
hyperplastic polyps can also be present, usually in association
with a hereditary disorder [54].
In the literature, large variations in neoplastic progression
rates of gastric hyperplastic polyps are documented. Focal car-
cinoma can be present in 0%–8% of hyperplastic polyps [55–
59]. The presence of a hyperplastic polyp appears to be asso-
ciated with an increased risk, up to 8.5%, of gastric cancer
development in the surrounding gastric mucosa [53, 60].
Large (> 10mm) hyperplastic polyps are more at risk of har-
boring dysplastic foci compared with small (< 10mm) hyper-
plastic polyps [59, 61]. Recurrence rates after the resection of
large hyperplastic polyps are high, up to 55% has been de-
scribed [61, 62].
3.7.3 Adenomas
Gastric adenomas can be found sporadically or in association
with familial polyposis syndrome. They appear as solitary, delin-
eated lesions that are often eroded (▶Fig. 2c). Adenomas can
be distinguished as tubular, villous, or tubulovillous adenomas.
Histologically, their differentiation can be intestinal or gastric.
Gastric differentiation includes pyloric gland adenomas, rare
foveolar adenomas, and even more rare oxyntic gland adeno-
mas. They may occur anywhere in the stomach, although they
are frequently encountered in the antrum.
Adenomas are associated with atrophic gastritis and gastric
cancer development in the surrounding gastric mucosa [63–
65]. According to the literature, foci of carcinoma are present
in up to 38% of adenomas [65–67]. Gastric adenomas are pre-
cancerous lesions with a risk of neoplastic progression.
▶ Fig. 2 Endoscopic images of the various types of gastric polyps: a fundic gland polyp; b hyperplastic polyp; c gastric adenoma (image 2c
courtesy of Dr. S.Mühldorfer).
RECOMMENDATION
ESGE recommends taking biopsies from (or resection of)
hyperplastic polyps of > 10mm.
Strong recommendation, low quality of evidence.
RECOMMENDATION
ESGE recommends biopsies from or, if endoscopically
resectable, resection of gastric adenomas.
Strong recommendation, moderate quality of evidence.
RECOMMENDATION
ESGE does not recommend standard biopsies of fundic
gland polyps.
Strong recommendation, low quality of evidence.





























High definition upper gastrointestinal endoscopy with
biopsy is the recommended diagnostic modality for all suspect-
ed cases of gastric neoplasia. Any lesion suspicious of neoplasia
should be sampled and sent to pathology in a separate con-
tainer.
Early gastric neoplasia is best staged and treated by endo-
scopic resection. Furthermore, extensive biopsy sampling can
jeopardize subsequent endoscopic resection by inducing scar-
ring and submucosal fibrosis. Therefore, for suspected neoplas-
tic gastric lesions that are potentially amenable to endoscopic
resection, the number of endoscopic biopsies should be
limited. One large retrospective study showed that two endo-
scopic biopsies yielded a 92.5% diagnostic accuracy for early
gastric neoplasia [68]. Therefore, two biopsies targeted on the
most suspicious parts of the lesion should be taken to docu-
ment the presence of dysplasia or neoplasia. Conversely, for
lesions not amenable to endoscopic resection (Paris classifica-
tion 0-I or 0-III, ulcerated lesions > 3 cm) where surgery or onco-
logic treatments will be requested, although three endoscopic
biopsies will yield a 98.3% sensitivity, at least six endoscopic
biopsies should be obtained, in order to assess the expression
of potential biomarkers, such as Her2neu [41, 69]. ▶Fig. 3 illus-
trates examples of early and advanced gastric neoplasia.
Obtaining a histologic diagnosis of gastric linitis plastica
(diffuse gastric cancer) can be challenging because tumor cells
▶ Fig. 3 Endoscopic images of gastric neoplasia showing: a, b early Paris type 0-IIb mucosal gastric cancer on: a white-light endoscopy (WLE);
b narrow-band imaging (NBI); c, d early Paris type 0-IIa submucosal gastric cancer on: cWLE; d near focus with NBI; e advanced ulcerative gastric
cancer (Borrmann type III); f linitis plastica (Borrmann type IV).
RECOMMENDATIONS
ESGE suggests obtaining at least 10 bite-on-bite biopsies
in cases of suspected gastric linitis plastica, targeting
mucosal abnormalities.
Weak recommendation, low quality of evidence.
ESGE suggests that, where there are negative biopsies
and a persisting suspicion of gastric linitis plastica, endos-
copy with more extensive biopsies can be repeated.
Endoscopic ultrasound (EUS) may be used to target biop-
sies or fine-needle aspiration/biopsy (FNA/B) of the most
affected part of the stomach.
Weak recommendation, low quality of evidence.
RECOMMENDATIONS
ESGE recommends at least six biopsies in cases of sus-
pected advanced gastric cancer.
Strong recommendation, moderate quality of evidence.
ESGE recommends taking only one to two targeted biop-
sies for lesions that are potentially amenable to endo-
scopic resection (Paris classification 0-II) to confirm the
diagnosis and allow subsequent endoscopic resection.
Strong recommendation, low quality of evidence.





























are diffusely spread in the gastric submucosa and stroma, and
the mucosa is often normal. Where there is a radiologic or
endoscopic suspicion of linitis plastica (presence of large folds,
gastric stenosis, circumferential thickening of at least one seg-
ment, lack of stomach distensibility, or thickening of the third
hyperechogenic layer on endoscopic ultrasound [EUS]) [70], it
is advisable to obtain at least 10 bite-on-bite biopsies of the
areas that appear most abnormal [71, 72]. If biopsies are nega-
tive, these can be repeated to obtain more tissue. As for CDH1
patients, the Cambridge protocol could be used [71, 72].
In addition, EUS can be used to identify the most affected
area of the stomach and to guide target biopsies or fine-needle
aspiration/biopsy (FNA/B). FNA of the gastric wall or suspicious
lymph nodes has been reported to be helpful in some cases, al-
though data are scarce [73–75]. Other possibilities for obtain-
ing tissue samples from the submucosa, such as submucosal
tunneling or prior endoscopic resection of overlying normal
mucosa, have been described but evidence on the efficacy and
safety of these techniques is very limited [76].
3.9 Celiac disease
Celiac disease is characterized by typical histologic changes.
Mucosal changes appear mostly in the proximal part of the
small intestine and may be patchy. Therefore, mucosal changes
may be missed if insufficient biopsies are obtained. Studies
have demonstrated that in patients with ultrashort celiac dis-
ease, pathology may be confined to the duodenal bulb [77].
Including biopsies from the bulb increases the diagnostic yield
of endoscopic biopsies for the diagnosis of celiac disease. ESGE
adheres to the advice from the World Gastroenterology Organi-
sation and American College of Gastroenterology, namely to
obtain at least six biopsies from different sites in the small
bowel, including two biopsies from the duodenal bulb, in
patients with a suspicion of celiac disease based on endoscopy
or serology [78–83].
This represents agreement between merged guidelines [78,
79]. No new evidence is available on this statement.
4 Hepatopancreatobiliary tract
4.1 Liver
Tissue sampling is often required for solid liver lesions or par-
enchymal liver disease. For both indications, the method of
choice is a percutaneous approach, which has been well estab-
lished and provides core samples for histologic diagnosis. EUS-
guided biopsy may be considered in specific situations, such as
anatomical issues, failure of percutaneous biopsy, or concomi-
tant indications for EUS. For example, EUS-guided liver biopsy
has recently been increasingly used for patients in whom diag-
nostic EUS is being performed to exclude extrahepatic biliary
obstruction [84], evaluate esophageal varices, or perform por-
tal pressure gradient measurement.
4.1.1 Liver tumors
For solid liver masses that are suspicious for malignancy or
metastases, histologic tissue sampling can be necessary to
decide on further patient management. Generally, tissue samp-
ling of these lesions is performed percutaneously. However, re-
cently, there have been reports on the use of EUS-FNA to sam-
ple solid liver masses suspicious for malignancy, with high spe-
cimen adequacy and diagnostic accuracy [85]. Although this in-
dication for EUS-FNA is relatively new and not yet clearly de-
fined, one may consider it in cases where lesions are poorly ac-
cessible or not detected by percutaneous imaging, or if
percutaneous sampling has repeatedly yielded an inconclusive
result.
4.1.2 Parenchymal liver disease
EUS-guided liver biopsy has been increasingly used, espe-
cially in patients in whom diagnostic EUS is being performed
to exclude extrahepatic biliary obstruction. Newer indications
may include patients with unknown liver disease undergoing
endoscopic evaluation of esophageal varices or portal pressure
gradient measurement. Generally, liver biopsy requires histo-
logic evaluation of a specimen of a minimum size and number
of portal tracts, making proper needle selection important. A
number of studies have evaluated and compared the use of
differently sized FNA needles and FNB. Samples adequate for
histopathologic evaluation were acquired more often with
19 G FNA needles or FNB, compared with smaller sized needles.
Factors such as the technique of biopsy may contribute to the
tissue yield rather than the needle itself [86–96].
RECOMMENDATION
ESGE suggests, where EUS-guided sampling is indicated,
the use of larger caliber needles (19G FNA or FNB
needles) in cases of suspected parenchymal liver disease.
Weak recommendation, low quality evidence.
RECOMMENDATION
ESGE suggests performing EUS-guided sampling of solid
liver masses suspicious for malignancy, if the pathologic
result will affect patient management and (i) the lesion
is poorly accessible/not detected at percutaneous imag-
ing, or (ii) a sample obtained via the percutaneous route
has repeatedly yielded an inconclusive result.
Weak recommendation, low quality of evidence.
RECOMMENDATION
ESGE recommends at least six biopsies from different
locations in the duodenum, including two samples from
the duodenal bulb, in patients with a suspicion of celiac
disease. Biopsies can be collected in the same container.
Strong recommendation, high quality of evidence.




























4.2 Pancreatic solid masses
Since the 2017 ESGE guideline on EUS-guided sampling [97],
a number of randomized trials and six meta-analyses compar-
ing FNA and FNB sampling in pancreatic masses have been pub-
lished. These publications support the recommendation from
2017 that FNA and FNB are recommended equally for the
sampling of pancreatic masses [98–114]. Overall, the diagnos-
tic yield does not differ between FNA and FNB needles [110,
113], but some studies indicate that the sample adequacy for
histologic evaluation is higher when using FNB compared with
FNA needles [99, 100, 111, 112]. There is some evidence sug-
gesting that the use of FNB results in more tissue and higher di-
agnostic accuracy with fewer needle passes than FNA [98–101,
104–106, 109, 111, 114], which may be relevant in cases where
core tissue is required for diagnosis or genetic profiling, or
when rapid onsite evaluation (ROSE) is not available. The hand-
ling of specimens is addressed below. Technical aspects of EUS-
guided tissue sampling are described in the 2017 ESGE clinical
guideline [97].
4.3 Bile ducts
The majority of biliary strictures are malignant (70%–80%),
with a limited number of causes (i. e. cholangiocarcinoma, pan-
creatic cancer, gall bladder carcinoma, metastatic disease, or
lymphoma). A benign etiology may also be found in 20%–30%,
with a much broader differential diagnosis (e. g. IgG4 disease,
primary sclerosing cholangitis, infection, post-trauma or post-
surgery, and vasculitis, among others) [115]. Early diagnosis of
biliary strictures is important for achieving optimal patient out-
comes and avoiding unnecessary surgical procedures. The
etiology of most biliary strictures can be diagnosed after a basic
work-up including transabdominal imaging, endoscopic retro-
grade cholangiopancreatography (ERCP) with standard trans-
papillary tissue sampling, or EUS-FNA/B in cases of suspected
pancreatic malignancy. Those cases in which this basic work-
up is non-diagnostic are referred to as indeterminate biliary
strictures.
4.3.1 Indeterminate biliary strictures
Studies have demonstrated a high sensitivity (75%–94%)
and diagnostic accuracy (79%–94%) for EUS-guided sampling
in indeterminate strictures, which is much higher than the sen-
sitivity (49%–60%) and diagnostic accuracy (60%–61%) for
ERCP-guided brush cytology [116–118].
For peroral cholangioscopy (POC), meta-analyses have re-
ported a sensitivity of 72%–94% and a specificity of 87%–99%
for cholangioscopy-guided biopsies in indeterminate strictures
[119–123]. The sensitivity and accuracy of POC were proved to
be higher than those of ERCP in indeterminate strictures in a
randomized study [124]. It suggested that POC may be prefer-
able for proximal and intrinsic strictures, whereas EUS-guided
tissue sampling may be preferable for distal and extrinsic stric-
tures [124, 125].
5 Miscellaneous
5.1 Biopsy handling, technical aspects
RECOMMENDATIONS
ESGE suggests performing peroral cholangioscopy (POC)
and/or EUS-guided tissue acquisition in indeterminate
biliary strictures. For proximal and intrinsic strictures,
POC is preferred. For distal and extrinsic strictures, EUS-
guided sampling is preferred, with POC where this is not
diagnostic.
Weak recommendation, low quality evidence.
ESGE suggests that performing POC with visually guided
biopsies provides the highest chance of confirming
malignancy.
Weak recommendation, moderate quality evidence.
RECOMMENDATIONS
ESGE recommends FNA and FNB needles equally for sam-
pling of solid pancreatic masses.
Strong recommendation, high quality evidence.
ESGE suggests using newer generation FNB needles (with
forward-facing bevels, fork tip, or crown tip) when the
aim is to obtain core tissue (e. g. neuroendocrine neo-
plasia, need for tumor genotype profiling) and when
rapid onsite evaluation (ROSE) is not available.
Weak recommendation, moderate quality evidence.
RECOMMENDATIONS
ESGE suggests that mucosal biopsy specimens are
released into labelled containers containing adequate
amounts of tissue fixation fluid (10% buffered formalin).
Weak recommendation, low quality of evidence.
ESGE recommends obtaining biopsies for microbial test-
ing or fresh biopsy material first, before the biopsy
forceps has come into contact with any tissue fixation
fluid.
Strong recommendation, low quality of evidence.
ESGE suggests obtaining possible non-neoplastic biopsies
before sampling suspected malignant lesions to prevent
intraluminal spread of malignant disease.
Weak recommendation, low quality of evidence.





























Proper biopsy handling is of paramount importance in max-
imizing clinical return and maintaining endoscopy quality
standards. Mucosal biopsy specimens should be gently released
into labelled biopsy containers containing adequate amounts of
tissue fixation fluid. Fixation stops cellular autolysis and pre-
pares tissues for embedding and sectioning. Although a range
of fixatives are available for specific downstream purposes (for
example glutaraldehyde for electron microscopy studies in
cases of pediatric failure to thrive), in general 10% buffered
formalin is the fixative of choice for mucosal biopsies. This is
compatible with point-of-care molecular (panel) sequencing
tests and the global standard for antigen retrieval in immuno-
histochemical studies. Comparative studies examining other
fixatives in standard endoscopy practice are not available.
If tissue material for microbial testing is required, this should
be secured first. If fresh biopsy material is required, for example
for molecular testing or enzymatic studies, this should not be
obtained with biopsy forceps that have come into contact with
any tissue fixation fluid. Studies have suggested that, in some
cases, biopsy instrumentation may facilitate intraluminal
spread of malignant disease, indicating that, where possible,
non-neoplastic biopsies should be secured before any suspect-
ed malignant lesions are sampled.
Direct communication with histopathology staff is encour-
aged to improve quality standards and ensure that specimens
are handled in line with institutional practices. For example,
work-up of endoluminal resection specimens and essential
pathology requisition details are best discussed within the con-
text of multidisciplinary team meetings and benefit greatly
from alignment between endoscopy and histopathology staff
[126, 127].
5.2 Type of biopsy forceps
Various studies have examined the impact of biopsy forceps
design on tissue adequacy in a pathologist-blinded fashion. Dif-
ferent types of biopsy forceps are available, with serrated jaws,
oval beaks, different jaw sizes, and with a spike to be able to
contain two biopsies within the cups of the forceps. Jumbo
biopsy forceps sample about three times the surface area com-
pared with standard cold biopsy forceps, but importantly do
not consistently provide deeper specimens. Despite variations
in the designs of different biopsy forceps and their claimed
benefits, studies agree that there are no reproducible differ-
ences in tissue adequacy or clinically relevant histopathologic
outcome [128–131].
5.3 Preparation of EUS-FNA material
Adequate preparation of FNA samples and dedicated train-
ing of cytotechnologists and pathologists are the prerequisites
for achieving optimal results. Cytologic tissue can be evaluated
using smears or liquid‑based cytology (LBC), or both. LBC mat-
erial can be further processed as thin preparations and/or cell
blocks.
Depending on the practical experience of the involved
pathology personnel, EUS‑FNA material could be divided into
smears (two per pass) and a cell block for additional evaluation.
Alternatively, the whole of the EUS-FNA material can be pro-
cessed as LBC, with a thin preparation as the first step and a
cell block as the second step (▶Fig. 4) [132–138].
Disclaimer









▶ Fig. 4 Diagram of the preparation of tissue specimens obtained
by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)
into smears and a cell block, or alternatively into liquid-based
cytology with a thin preparation as the first step and a cell block as
the second step.
RECOMMENDATION
ESGE suggests dividing EUS-FNA material into smears
(two per pass) and liquid-based cytology (LBC), or the
whole of the EUS-FNA material can be processed as LBC,
depending on local experience.
Weak recommendation, low quality evidence.
RECOMMENDATION
ESGE suggests the use of a standard cold biopsy forceps,
because there is too little benefit in terms of histopatho-
logic outcome to recommend the use of a jumbo biopsy
forceps.
Weak recommendation, moderate quality of evidence.
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